BioArctic AB (publ) (BIOA-B.ST)
SEK 170.0
(-0.93%)
SEK 170.0
(-0.93%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 615.99 Million SEK | 169.83% |
| 2022 | 228.29 Million SEK | 886.31% |
| 2021 | 23.14 Million SEK | -62.88% |
| 2020 | 62.34 Million SEK | -77.87% |
| 2019 | 281.77 Million SEK | -60.53% |
| 2018 | 713.97 Million SEK | 407.42% |
| 2017 | 140.7 Million SEK | 33.23% |
| 2016 | 105.61 Million SEK | 154.04% |
| 2015 | 41.57 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 49.84 Million SEK | 68.17% |
| 2024 Q1 | 29.63 Million SEK | 168.86% |
| 2023 Q1 | 393.42 Million SEK | 18724.21% |
| 2023 Q4 | 11.02 Million SEK | -94.72% |
| 2023 Q2 | 2.7 Million SEK | -99.31% |
| 2023 Q3 | 208.83 Million SEK | 7617.59% |
| 2023 FY | 615.99 Million SEK | 169.83% |
| 2022 Q3 | 218.22 Million SEK | 5046.82% |
| 2022 FY | 228.29 Million SEK | 886.31% |
| 2022 Q4 | 2.09 Million SEK | -99.04% |
| 2022 Q2 | 4.24 Million SEK | 13.46% |
| 2022 Q1 | 3.73 Million SEK | -20.59% |
| 2021 Q2 | 7.31 Million SEK | 1.88% |
| 2021 Q1 | 7.17 Million SEK | -14.16% |
| 2021 Q4 | 4.7 Million SEK | 19.08% |
| 2021 Q3 | 3.95 Million SEK | -45.95% |
| 2021 FY | 23.14 Million SEK | -62.88% |
| 2020 Q3 | 10.54 Million SEK | 50.55% |
| 2020 Q4 | 8.36 Million SEK | -20.74% |
| 2020 FY | 62.34 Million SEK | -77.87% |
| 2020 Q1 | 36.43 Million SEK | 37.88% |
| 2020 Q2 | 7 Million SEK | -80.77% |
| 2019 FY | 281.77 Million SEK | -60.53% |
| 2019 Q4 | 26.42 Million SEK | 28.07% |
| 2019 Q3 | 20.63 Million SEK | -87.96% |
| 2019 Q2 | 171.33 Million SEK | 170.29% |
| 2019 Q1 | 63.38 Million SEK | -87.7% |
| 2018 FY | 713.97 Million SEK | 407.42% |
| 2018 Q2 | 52.3 Million SEK | -0.0% |
| 2018 Q4 | 515.32 Million SEK | 447.95% |
| 2018 Q1 | 52.3 Million SEK | 2.51% |
| 2018 Q3 | 94.04 Million SEK | 79.81% |
| 2017 Q3 | 31.49 Million SEK | -1.64% |
| 2017 FY | 140.7 Million SEK | 33.23% |
| 2017 Q4 | 51.02 Million SEK | 62.01% |
| 2017 Q2 | 32.01 Million SEK | 22.33% |
| 2017 Q1 | 26.17 Million SEK | -72.29% |
| 2016 Q1 | 4.99 Million SEK | 0.0% |
| 2016 FY | 105.61 Million SEK | 154.04% |
| 2016 Q4 | 94.44 Million SEK | 7889.85% |
| 2016 Q3 | 1.18 Million SEK | 18.08% |
| 2016 Q2 | 1 Million SEK | -79.96% |
| 2015 FY | 41.57 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | -960.105% |
| Ziccum AB (publ) | 3.74 Million SEK | -16339.685% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | -1120.155% |
| Mendus AB (publ) | 28.48 Million SEK | -2062.372% |
| Genovis AB (publ.) | 158.23 Million SEK | -289.299% |
| Intervacc AB (publ) | 8.01 Million SEK | -7585.527% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -13983.105% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | -261.415% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | -1303.306% |
| Aptahem AB (publ) | 2.63 Million SEK | -23316.094% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -59416.425% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -799893.506% |
| Fluicell AB (publ) | 3.33 Million SEK | -18354.014% |
| Saniona AB (publ) | 16.84 Million SEK | -3557.928% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | -3654.465% |
| Biovica International AB (publ) | 7.29 Million SEK | -8349.863% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -51104.904% |
| AcouSort AB (publ) | 10.55 Million SEK | -5738.262% |
| Xintela AB (publ) | 78 Thousand SEK | -789637.179% |
| Abliva AB (publ) | 137 Thousand SEK | -449531.387% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | -969.436% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -30485.65% |
| OncoZenge AB (publ) | 3000.00 SEK | -20533066.667% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -397316.129% |
| CombiGene AB (publ) | 5.54 Million SEK | -11010.786% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 48.96% |
| Camurus AB (publ) | 1.71 Billion SEK | 64.121% |
| Corline Biomedical AB | 25.03 Million SEK | -2361.027% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -10748.802% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -85336.2% |
| I-Tech AB | 120.86 Million SEK | -409.672% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | -359.376% |
| Cyxone AB (publ) | 5.14 Million SEK | -11865.715% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -8637.518% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -5676.018% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -5385.232% |
| Nanologica AB (publ) | 1.44 Million SEK | -42588.496% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -1162154.717% |
| BioInvent International AB (publ) | 71.46 Million SEK | -762.002% |
| Alzinova AB (publ) | 270 Thousand SEK | -228046.296% |
| Oncopeptides AB (publ) | 35.22 Million SEK | -1648.992% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -42004.346% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -21728.313% |
| Simris Alg AB (publ) | 4.35 Million SEK | -14047.795% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -473742.308% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | -158.031% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -2678139.13% |